RISPERDAL CONSTA® (risperidone)
The first FDA-approved, long-acting, injectable, atypical antipsychotic indicated for the maintenance treatment of Bipolar I Disorder as monotherapy
Helping to provide predictability*† for more of your adult patients with Bipolar I Disorder when administered every 2 weeks.1
†While no medication can guarantee adherence, using a long-acting, professionally administered medication can help you recognize a missed dose and intervene.